2 highly rated ASX 200 shares to buy immediately

Here are two buy-rated ASX 200 shares to snap up today…

| More on:
A man working in the stock exchange.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ASX 200 is home to some high quality companies that have significant long term potential.

Two that have recently been rated as buys are listed below. Here's why these ASX 200 shares could be in the buy zone:

CSL Limited (ASX: CSL)

The first ASX 200 share to look at is biotherapeutics giant CSL. Its CSL Behring and Seqirus businesses have a portfolio of life-saving and lucrative therapies and vaccines which are generating billions of dollars in sales each year.

But management never rests on its laurels. Each year it invests in the region of 10% to 11% of its sales back into research and development (R&D) activities. This means that CSL will be investing around US$1 billion into its R&D this year. This ensures that the company has pipeline of therapies under development that could drive its future growth.

In addition, CSL is in the process of acquiring Vifor Pharma for ~$17 billion. Management notes that the deal expands its leadership across an attractive portfolio focused on renal disease and iron deficiency. It also highlights that Vifor has a high quality pipeline and complements CSL's existing therapeutic focus areas including Haematology, Thrombosis, Cardiovascular, and Transplant.

Citi is bullish on CSL and has a buy rating and $340.00 price target on its shares.

ResMed Inc. (ASX: RMD)

Another ASX 200 share to look at is ResMed. It is a leading sleep treatment-focused medical device company with a portfolio of products improving the lives of sufferers of conditions such as sleep apnoea.

ResMed has been growing at a solid rate for well over a decade and shows no signs of stopping any time soon. This is due to its leadership position in a market which continues to grow as education around sleep disorders improves.

In addition, with one of its key competitors continuing to work its way through a massive product recall, ResMed looks well-placed to win market share. This, combined with its patient-centric, connected-care digital platform, bodes well for its growth in the coming years.

Morgans is a big fan of the company and has an add rating and $40.46 price target on its shares.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Blue Chip Shares

A young woman sits on a sofa in a stylish home with her laptop computer balanced on her knee and smiles with a satisfied look on her face at what she's seeing on the screen.
Blue Chip Shares

2 ASX blue-chip shares offering big dividend yields

These stocks could provide strong passive income.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Blue Chip Shares

3 ASX 200 blue chip shares to buy with $3,000 in July

Analysts have recently named these well-known stocks as top buys.

Read more »

Two people having a meeting using a laptop and tablet to discuss Seven West Media's balance sheet
Blue Chip Shares

3 fantastic ASX shares to buy for an SMSF

Let's see why these shares that brokers rate as buys could be top picks for super investors.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Blue Chip Shares

Buy these fantastic ASX 200 blue chips with $10,000

Analysts think these top stocks are buys right now.

Read more »

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Blue Chip Shares

The best ASX shares to buy and forget for 10+ years

Want to make long term investments? Here are three picks that brokers rate as buys.

Read more »

An ASX investor in a business shirt and tie looks at his computer screen and scratches his head with one hand wondering if he should buy ASX shares yet
Blue Chip Shares

This popular ASX 200 blue-chip share has literally gone nowhere in 17 years

Even blue-chip shares can fall short.

Read more »

Two smiling work colleagues discuss an investment or business plan at their office.
Blue Chip Shares

3 no-brainer ASX shares to buy now with $5,000

Brokers think these shares could be among the best to buy right now.

Read more »

Broker checking out the share price oh his smartphone and laptop.
Blue Chip Shares

2 ASX blue-chip shares offering big dividend yields

These businesses are predicted to pay significant passive income to shareholders.

Read more »